title: Effects of sildenafil on blue-on-yellow and white-on-white Humphrey perimetry in 3 months regular use.
abstract: OBJECTIVE
  To assess the effects of sildenafil on blue-on-yellow (B/Y) and white-on-white (W/W) Humphrey perimetry in a group of men with erectile dysfunction in 3 months regular use.
  
  
  METHODS
  In this prospective study, 14 patients with erectile dysfunction received 50 mg doses of sildenafil (Viagra, Pfizer) two times per week regularly for 3 months. Patients underwent best-corrected visual acuity (BCVA), colour vision, anterior segment and fundus examination, and B/Y and W/W Humphrey perimetry in each eye before and after sildenafil treatment. Changes in mean deviations (MD) were compared separately for both eyes.
  
  
  RESULTS
  No significant changes from baseline were observed in BCVA and colour vision after sildenafil treatment. The anterior segment and fundus examinations revealed no abnormalities. There was no change on B/Y and W/W Humphrey visual field. MD values of B/Y and W/W Humphrey perimetry remained nonsignificant for both eyes after 3 months regular use of sildenafil (P=0.133, and 0.092, respectively, for right, and P=0.221 and 0.925, respectively, for left eyes).
  
  
  CONCLUSIONS
  Oral sildenafil used regularly for 3 months produced no effect on B/Y and W/W Humphrey perimetry.
authors.affiliation: Department of Ophthalmology, Faculty of Medicine, Adnan Menderes University, Aydin, Turkey. orucs@yahoo.com
authors.forename: S O
authors.initials: SO
authors.lastname: Dündar
authors.forename: A
authors.initials: A
authors.lastname: Topalo Gcaron Lu
authors.forename: M
authors.initials: M
authors.lastname: Dündar
authors.forename: I
authors.initials: I
authors.lastname: Koçak
mesh_terms: D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors; D000284:Administration, Oral; D000328:Adult; D003118:Color Perception / Q000187:drug effects*; D004334:Drug Administration Schedule; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000503:physiopathology; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D011687:Purines / Q000008:administration & dosage / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D058609:Visual Field Tests / Q000379:methods*; D014794:Visual Fields / Q000187:drug effects* / Q000502:physiology
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate; D015106:3',5'-Cyclic-GMP Phosphodiesterases